Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients

Cancer Science

Volumn 101, Issue 10, 2010, Pages 2278-2285

  Iida, Shinya ^a   Miki, Yasuhiro ^a   Ono, Katsuhiko ^a   Akahira, Jun Ichi ^a   Suzuki, Takashi ^a   Ishida, Kazuyuki ^b   Watanabe, Mika ^b   Sasano, Hironobu ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4A; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CELL PROLIFERATION; CLUSTER ANALYSIS; CORRELATION ANALYSIS; ENZYME ACTIVATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; JAPANESE; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; AGED; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; CLUSTER ANALYSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PROTEIN-SERINE-THREONINE KINASES; TOR SERINE-THREONINE KINASES;

EID: 77957053041     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01657.x     Document Type: Article

References (39)

1. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004, 1014:13-27.
2. Ito T, Sasano H, Tanaka M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010, 45:234-43.
3. Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician 2006, 74:429-34.
4. Schnirer II, Yao JC, Ajani JA. Carcinoid - a comprehensive review. Acta Oncol 2003, 42:672-92.
5. Ono K, Suzuki T, Miki Y. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogues SOM230 on cell proliferation in cell line NCI-H727. Anticancer Res 2007, 27:2231-40.
6. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 2000, 62:84-91.
7. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-48.
8. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124:471-84.
9. Pouysségur J, Dayan F, Mazure N. Hypoxia signaling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-43.
10. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signaling. Biochem Soc Trans 2003, 31:573-8.
11. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-76.
12. von Wichert G, Jehle PM, Hoeflich A. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumors cells. Cancer Res 2000, 60:4573-81.
13. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon P, Caplin ME. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006, 18:355-60.
14. Meijinen P, Perterse JL, Antonini N, Rutgers EJTh, van de Vijver MJ. Immunohistochemical categorization of ductal carcinoma in situ of the breast. Br J Cancer 2008, 98:137-42.
15. Carvalho JC, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical markers in leimyosarcoma delineates specific anatomic and gender subgroups. Cancer 2009, 115:4186-95.
16. Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008, 103:729-32.
17. Papotti M, Bongiovanni M, Valante E. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002, 440:461-75.
18. Jais P, Terris B, Ruszniewski P. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 1997, 27:639-44.
19. Rindi G, Klöppel G, Alhman H. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-8.
21. Gardner N. Targeting the mTOR pathway in neuroendocrine tumors. Clin J Oncol Nurs 2009, 13:558-63.
22. Yao JC. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Clin Endocrinol Metab 2007, 21:163-72.
23. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003, 2:999-1017.
24. Rinke A, Muller HH, Schade-Brittinger C. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009, 27:4656-63.
25. Grozinsky-Glasberg S, Franchi G, Teng M. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumor cell line. Neuroendocrinology 2008, 87:168-81.
26. Arnold R, Trautmann ME, Creutzfeldt ME. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996, 38:430-8.
27. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WI. Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999, 158:284-7.
28. Basu TN, Gutmann DH, Fletcher JA. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-5.
29. Gutmann DH, Aylsworth A, Carey JC. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-7.
30. Hopfner M, Baradari V, Huether A. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006, 13:135-49.
31. Tolcher AW, Rothenberg ML, Rodon J. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007, 25:3002.
32. Jayaraman T, Marks AR. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J Biol Chem 1993, 268:25385-8.
33. Vilella-Bach M, Nuzzi P, Fang Y. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem 1999, 274:4266-72.
34. Motzer RJ, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. The Lancet 2008, 372:449-56.
35. Hudes G, Carducci M, Tomczak P. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFR in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 2006, 24.
36. Zitzmann K, De Toni EN, Brand S. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85:54-60.
37. Duran I, Kortmansky J, Singh D. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95:1148-54.
38. Moreno A, Akcakanat A, Munsell MF. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008, 15:257-66.
39. Endo H, Murata K, Mukai M. Activation of insulin-like growth factor signaling induces apoptotic cell death under prolonged hypoxia by enhancing endoplasmic reticulum stress response. Cancer Res 2007, 67:8095-103.